Nuvation Bio Inc. (NUVB) is a publicly traded Healthcare sector company. As of May 20, 2026, NUVB trades at $4.45 with a market cap of $1.47B and a P/E ratio of -10.73. NUVB moved +6.49% today. Year to date, NUVB is -47.50%; over the trailing twelve months it is +107.83%. Its 52-week range spans $1.54 to $9.75. Analyst consensus is strong buy with an average price target of $13.17. Rallies surfaces NUVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nuvation Bio Completes Thermo Fisher Tech Transfer for IBTROZI Manufacturing: Nuvation Bio completed process technology transfer of IBTROZI to Thermo Fisher Scientific and filed the U.S. manufacturing supplement to its New Drug Application. The company also presented at the Bank of America Global Healthcare Conference 2026, detailing its oncology pipeline and commercial strategy.
| Metric | Value |
|---|---|
| Price | $4.45 |
| Market Cap | $1.47B |
| P/E Ratio | -10.73 |
| EPS | $-0.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.75 |
| 52-Week Low | $1.54 |
| Volume | 4.47M |
| Avg Volume | 0 |
| Revenue (TTM) | $143.05M |
| Net Income | $-145.99M |
| Gross Margin | 0.00% |
7 analysts cover NUVB: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.17.